H
eart failure (HF) is complex pathophysiological and clinical syndrome that continues to be a leading cause of morbidity, hospitalization, and mortality.
1,2 Although significant improvement in HF survival has been observed over the last few decades, 3 largely because of the identification and increased use of pharmacological therapies that improve outcomes such as those targeting the renin-angiotensin-aldosterone system, 4 the 5-year mortality and rates of hospitalization remain unacceptably high. 1 Because of this, the discovery and development of novel pharmacotherapies remain paramount to improving outcomes in HF.
In 2014, a major breakthrough in HF therapeutics occurred with the publication of the results of the PAR-ADIGM-HF trial (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With AngiotensinConverting Enzyme Inhibitor [ACEi] to Determine Impact on Global Mortality and Morbidity in HF) which was stopped after a median follow-up of 27 months because of a significant reduction in morbidity and mortality in participants receiving AngII receptor blocker neprilysin inhibitor. 5 Specifically, McMurray et al 5 reported that LCZ696, a first in class small molecule that delivers simultaneous angiotensin receptor blockade via valsartan and neprilysin inhibition via sacubitril, significantly reduced all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril in patients with HF with reduced ejection fraction (HFrEF). Given these results from a single, multicenter, international, doubleblind, randomized trial, the US Food and Drug Administration (FDA) approved sacubitril/valsartan (Entresto, Novartis) for use in patients with chronic HFrEF and New York Heart Association functional classes II to IV symptoms in July 2015. Approval by the European Commission then followed in November 2015. Less than a year later, sacubitril/valsartan received a class I recommendation for use in chronic symptomatic HFrEF in both the US and European HF clinical practice guidelines. 6, 7 Since approval and the incorporation of sacubitril/ valsartan into the HF guidelines, the adoption of sacubitril/valsartan into real-world clinical practice in the US has yet to be described. Thus, the goal of this study was aimed to assess the adoption, continuation, and prescription cost of sacubitril/valsartan in its first year after FDA approval in individuals enrolled in US commercial and Medicare Advantage health plans.
METHODS

Data Source
We conducted a retrospective analysis using the OptumLabs Data Warehouse, a large database including over 100 million individuals with private and Medicare Advantage health plans. 8, 9 The database comprises of medical and pharmacy claims for individuals in all 50 states and of all ages and ethnic and racial groups. Medical claims include claims for professional (eg, physician), facility (eg, hospital), and outpatient prescription medication services. Pharmacy claims include fill date, strength, days supply, prescriber specialty, generic/ brand names, and paid amounts (out-of-pocket [OOP] and health plan paid amounts). The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure, as access to the data requires a partnership with OptumLabs. Pursuant to the Health Insurance Portability and Accountability Act, the use of deidentified data does not require Institutional Review Board approval.
Study Populations
First, we identified all individuals 18 years or older who filled a prescription for sacubitril/valsartan between July 1, 2015, and December 31, 2016 (sacubitril/valsartan cohort). For each individual, we defined the index initiation date as the date of first fill date of sacubitril/valsartan.
To contextualize and understand which patients with HFrEF were initiated on sacubitril/valsartan, we also identified all patients with systolic HF (HFrEF cohort). We relied on billing codes for systolic HF, an approach which has been demonstrated to be 97.7% specific for identifying individuals with HF and an EF <45%. 10 We included those with a single inpatient claim or at least 2 outpatient claims on different dates ( 
WHAT IS NEW?
• In this claims-based cohort study, adoption of sacubitril/valsartan was slow after Food and Drug Administration approval. • Sacubitril/valsartan was more often prescribed in patients with heart failure with reduced ejection fraction who were younger, male, and had less comorbidity.
• Out-of-pocket and insurer-paid prescription drug costs were much higher than other guidelinedirected heart failure therapies.
• In total, 40.9% of patients were nonadherent/discontinued sacubitril/valsartan in the first 6 months after initiation. Nonadherence and discontinuation were more common in Black patients and patients who had not previously been taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Slow adoption of sacubitril/valsartan may be associated with the high cost.
• Factors contributing to the high rates of nonadherence/discontinuation observed in this study require further exploration.
et al. 11 We defined the index date as the date of first billing code for systolic HF during the study period.
Finally, as we were interested in identifying differences in characteristics of patients initiated on sacubitril/valsartan with those who were eligible for initiation, we identified the subset of patients with HFrEF who were treated with an ACEi or angiotensin receptor blocker (ARB) and did not receive sacubitril/valsartan during the study period (HFrEF ACEi/ARB cohort). We selected those adults with a billing code for systolic HF that filled a prescription for an ACEi or ARB. The index date was the date of first fill of an ACEi or ARB during the study period.
We required all patients to have continuous enrollment in a medical and prescription drug plan for at least 6 months before their index date.
Independent Variables
Independent variables of interest at index included age, sex, race/ethnicity, residence region, health plan coverage, comorbidities, prescription medications, and prescriber specialty. Comorbidities were captured by International Classification of Diseases, 9th Edition and International Classification of Diseases, 10th Edition codes in any position on claims in the 6 months before the index date. 12 Comorbidity burden was assessed using the Charlson comorbidity index. 12 For each patient in the sacubitril/valsartan and HFrEF ACEi/ARB cohorts, we assessed prescriber specialty, categorizing as cardiologist, primary care (family medicine, internal medicine), or other. Use of other HF medications in the 90 days before index date was determined based on pharmacy claims. Monthly OOP and health plan (insurer) costs of sacubitril/valsartan and other commonly used HF medications were determined based on the pharmacy claims. Total number of medications (other than ACEi/ARB and sacubitril/valsartan) at index date was assessed by therapeutic class using pharmacy claims. The total OOP cost of all medications (other than ACEi/ARB and sacubitril/valsartan) at index date was calculated. For those filling prescriptions for other than 30 days supply, a 30-day supply cost was calculated.
Sacubitril/Valsartan Adherence and Dose Titration
We obtained pharmacy fills for the 180-day period after initiation of sacubitril/valsartan. Pharmacy claims are complete with a 3-month lag in the OptumLabs Data Warehouse. Patients who ended coverage within 180 days of first fill were excluded from analysis. Medication adherence/continuation was calculated by the proportion of days covered. The numerator was the number of days supply in the first 180 days after initiation, and the denominator was 180. As medications are provided to patients in the hospital, days hospitalized were added to the numerator. Nonadherence was defined as a proportion of days covered <80%. 13 We recognize that patients may choose to stop taking a prescription medication for several reasons, such as cost and intolerance, and may make the decision in conjunction with their physician or on their own. Although we cannot fully distinguish these reasons using pharmacy claims, we hypothesized that patients who stopped after discussion with their physician would often resume treatment with an ACEi or ARB. As such, we examined the proportion of patients that failed to refill sacubitril/ valsartan that filled an ACEi or ARB in the follow-up period. Titration of sacubitril/valsartan in the 180 days after initiation was determined based on the doses of initial and subsequent fills. Available doses include 24 mg sacubitril/26 mg valsartan, 49/51 mg, and 97/103 mg.
Statistical Analysis
Baseline characteristics of the sacubitril/valsartan and HFrEF ACEi/ARB cohorts are reported as frequencies with percentages for categorical data and means with SDs for continuous variables. Differences in baseline characteristics in patients in the 2 cohorts were compared using χ 2 tests for categorical variables and t tests for continuous variables. Logistic regression was used to assess predictors of use of sacubitril/valsartan versus ACEi/ARB with results presented as odds ratios and 95% confidence intervals.
The proportion of beneficiaries with HFrEF (denominator) who were taking sacubitril/valsartan (numerator) in each month of the study period was calculated. Univariate and multivariate logistic regression were used to assess predictors of adherence (proportion of days covered ≥80%) to sacubitril/ valsartan in the 180 days after initiation with data presented as odds ratios and 95% confidence interval. All analyses were conducted using SAS 9.4 (SAS Institute Inc, Cary, NC).
RESULTS
Population Characteristics
The baseline characteristics of patients taking sacubitril/ valsartan and those with HFrEF taking an ACEi/ARB in the study period are shown in Table 1 . A total of 102 247 patients had HFrEF, of whom 39 598 were taking an ACEi/ ARB but not sacubitril/valsartan in the study period. A total of 2244 patients filled a new prescription for sacubitril/valsartan in the 18 months after FDA approval, which was predominantly prescribed by a cardiologist (82%). A majority of patients were initiated on the 24/26 mg dose (58.6%), with fewer initially filling 49/51 mg (32%) and 97/103 mg (9.4%). Many patients (43.9%) initiated on sacubitril/valsartan were not taking an ACEi or ARB in the 90 days before initiation. Only a small proportion filled their first prescription for sacubitril/valsartan within 7 days (3%) and 30 days (9%) of discharge after a hospitalization, suggesting that the vast majority of patients are initiated on sacubitril/valsartan in the outpatient setting. Compared with patients taking ACEi/ARB, those taking sacubitril/valsartan were younger (mean age, 67.6 versus 70.3 years), more often male (68.2% versus 58.5%), and had fewer comorbidities. Patients filling sacubitril/valsartan were also more likely to be using other commonly prescribed HF medications at baseline, but were taking fewer total medications (Table 1) . Adjusting for potential confounders, use of other HF medications was associated with greater odds of receiving sacubitril/valsartan, whereas older age, female sex, chronic obstructive pul-monary disease, cerebrovascular disease, dementia, and use of a greater total number of prescription medications were associated with lower odds of receiving sacubitril/ valsartan. Differences by region and race/ethnicity were also observed ( Figure 1) 
Monthly Trends in Initiation of Sacubitril/ Valsartan
The number of patients initiating sacubitril/valsartan steadily increased after its market debut in July 2015 (Figure 2A) . However, the overall proportion of patients with HFrEF taking sacubitril/valsartan remained low (maximum 2.3%) throughout the study period (Figure 2B ).
Monthly Costs
The average monthly costs incurred by patients and insurers for sacubitril/valsartan and other common HF medications are shown in Figure 3 . Both OOP and insurer costs for sacubitril/valsartan were substantially higher than costs for other guideline-directed HFrEF medications including lisinopril, losartan, carvedilol, ACEi/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; HFrEF, heart failure with reduced ejection fraction; IQR, interquartile range; and OOP, out-of-pocket.
*At time of initiation of sacubitril/valsartan or date of first fill of ACEi/ARB in the study period. 
Sacubitril/Valsartan Adherence/ Continuation
Overall, 1161 of the 1964 (59.1%) patients were adherent to sacubitril/valsartan in the 180 days after initiation. Of those who were nonadherent (n=803), 393 (48.9%) did not refill a prescription for sacubitril/valsartan for >30 days after their supply ended, suggesting that they discontinued sacubitril/valsartan. Of those who were nonadherent/discontinued sacubitril/valsartan (n=803), 160 (20%) switched to an ACEi/ARB. The univariate and multivariate predictors of 180-day medication adherence/continuation are shown in Table 2 . Adjusting for potential confounders, higher rates of nonadherence observed in Black patients, those with chronic obstructive pulmonary disease, and patients residing in the South. Better adherence was observed in patients previously on an ACEi/ARB, those taking a higher number of total medications, and those initiated on the 97/103 mg dose. We found no association of OOP costs of sacubitril/valsartan with adherence/continuation (odds ratio for adherence per $10 increase, 0.999; 95% confidence interval, 0.992-1.006; P=0.76).
Sacubitril/Valsartan Dose Titration
Of the 1161 patients who continued sacubitril/valsartan for 180 days after initiation, 355 (30.6%) had a dose titration (Figure 4) . A majority of patients were started on the 24/26 mg dose, 26% of whom titrated up in the 180 days after initiation. A similar proportion of those initiated on 49/51 mg were titrated up to 97/103 mg after initiation (29%), whereas a small proportion was titrated down to 24/26 mg (5%). A small number of patients were initiated on 97/103 mg, very few of whom titrated down during follow-up (3%). In total, 285 (24.5%) patients were taking 97/103 mg of sacubitril/valsartan by the end of the study period.
DISCUSSION
There are several important findings from this study.
In this large population of individuals with HF enrolled in US private and Medicare Advantage health plans, adoption of sacubitril/valsartan was slow in the first 18 months after FDA approval. There were systematic differences in the characteristics of individuals initiated on sacubitril/valsartan compared with others with HFrEF, in that they were younger, more often male, and had fewer comorbidities. In addition, the observed OOP costs for sacubitril/valsartan were much higher than other guideline-directed medical therapies for HFrEF and may represent an important barrier to initiation and continuation. Finally, many patients initiated on sacubitril/valsartan discontinued use in the first 180 days. Sacubitril/valsartan is a new drug class that simultaneously blocks the renin-angiotensin-aldosterone system and inhibits neprilysin, the enzyme responsible for the degradation of the natriuretic peptides and other peptides.
14,15 Despite a class I recommendation for use of sacubitril/valsartan in the 2016 HF guidelines, 7 the adoption after FDA approval in this HFrEF population was slow. While use slowly increased over time, 18 months after FDA approval only 2.3% of patients with HFrEF were taking sacubitril/valsartan. These findings can be compared with a recent report from the Get With The Guidelines (GWTG) HF registry. Among patients hospitalized with HFrEF at GWTG-participating hospitals from July 2015 to June 2016, the authors examined how often sacubitril/valsartan was listed as a discharge medication. Similar to our report, they found that sacubitril/valsartan was documented in only 2% of patients and that older individuals and those with more comorbid conditions were less likely to be taking sacubitril/valsartan. 16 However, unlike the GWTG report, our study captured actual prescription fills by patients, rather than documentation of sacubitril/valsartan on a discharge medication list. Our findings suggest that the vast majority of patients are initiated on sacubitril/ valsartan in the outpatient setting, as only 9% filled a new prescription within 30 days of hospital discharge. As such, the GWTG analysis may have been detecting prevalent users. Alternatively, patients who were prescribed sacubitril/valsartan at discharge may have never filled the prescription because of cost or other factors, underscoring the importance of inclusion of pharmacy data in our analysis. The access to pharmacy data also enabled us to provide novel information about adher- ence, continuation, and cost of sacubitril/valsartan, which was not possible in GWTG.
It is important to contextualize the early adoption of sacubitril/valsartan compared with other pharmacological therapies for patients with a chronic condition. After publication of the results of the RALES trial (Randomized Aldactone Evaluation Study) of spironolactone versus placebo in HFrEF in 1999, 17 the rate of spironolactone use in Medicare beneficiaries with HFrEF tripled over the next 18 months. 18 However, spironolactone had already been in use in clinical practice for other indications such as hypertension, and as such, many physicians may have been more willing to adopt the medication for use in HFrEF when compared with a newly developed medication like sacubitril/valsartan. By comparison, after FDA approval of the first novel oral anticoagulant, dabigatran, for use in nonvalvular atrial fibrillation, it was prescribed to ≈10% of patients with nonvalvular atrial fibrillation, constituting ≈20% of all oral anticoagulant prescriptions, over the next 18 months. 19 However, dabigatran offered a large convenience advantage to patients over warfarin, as it did not require international normalized ratio monitoring and may have contributed to its strong early adoption. Finally, many novel medications to treat the chronic serious illness hepatitis C have been FDA approved since 2011. These medications offer shorter treatment periods and are more effective and tolerable than older regimens (interferon alfa and ribavirin), but are also more expensive. In one claims-based study, although only 10% of patients with hepatitis C received any treatment, by the end of 2014, essentially all patients treated were receiving the newer medications. 20 Thus, compared with other selected examples of novel treatments in chronic serious illness, adoption of sacubitril/valsartan has been slow.
Cost is an important potential barrier to use of sacubitril/valsartan. Both the insurer-paid and OOP costs for sacubitril/valsartan were several orders of magnitude higher than other guideline-based HFrEF medications. These high costs can contribute to multi-level barriers to initiation and continuation. Insurers often impose strict coverage criteria, prior authorizations, and tiered OOP coverage to deter unnecessary use. UnitedHealthcare, the largest insurer represented in this data source, has instituted both prior authorization and the highest tier prescription coverage (tier 3) for sacubitril/valsartan, such that patients are required to pay a higher cost to fill. While intended to promote appropriate drug use, time-consuming prior authorizations can be a deterrent to clinician prescribing. 21 Finally, higher OOP costs not The mean out-of-pocket costs (A) and insurer-paid costs (B) for sacubitril/valsartan and other common medications used to treat patients with heart failure with reduced ejection fraction are shown.
only deter patient initiation of a medication but can also negatively impact adherence and outcomes. 22, 23 Most patients with HF are taking numerous daily medications and, in the absence of unlimited financial resources, are often faced with important decisions about what they can afford to allocate toward a single medication, even if effective at improving outcomes. Insurer coverage of sacubitril/valsartan may change after results of additional clinical trials that are underway, and the manufacturer (Novartis) now offers financial assistance such as a free 30-day trial and reduced copay cards to help individuals afford the OOP costs.
Some would argue that the clear demonstration of efficacy of sacubitril/valsartan in the PARADIGM-HF trial is sufficient to warrant widespread adoption in patients with chronic symptomatic HFrEF. 24 However, in an era where HF care already accounts for >18 billion dollars annually in the United States, 25 considering cost in addition to efficacy is important in determining value of a new treatment. In several analyses using data from PAR-ADIGM-HF, [26] [27] [28] [29] the incremental cost-effectiveness ratio ranged from $45 017 to $50 959 per quality-adjusted life year over a lifetime, a level relatively consistent with other accepted invasive cardiovascular interventions. 30 By comparison, the cost-effectiveness of other HFrEF pharmacological therapies, such as ACEi, β-blockers, and aldosterone antagonists, is much more favorable (<$10 000 per quality-adjusted life year). 31 However, higher costs are expected with newly released medications, and medications with higher associated costs may have value if there is a significant gain in quality-adjusted life year. The existing cost-effectiveness analyses for sacubitril/valsartan are limited to data obtained from a single clinical trial, and real-world outcomes data are needed to determine true effectiveness. In our study, patients taking sacubitril/valsartan were older (mean, 68 versus 64 years), more often female (32% versus 21%), Black (17% versus 5%), and had higher prevalence of comorbidities such as diabetes mellitus (45% versus 35%) than patients enrolled in the PARADIGM-HF trial. 5 The effectiveness and impact on outcomes of sacubitril/valsartan in patients who were not well represented in PARADIGM-HF may differ.
Even if we decide that sacubitril/valsartan is a highvalue treatment in HFrEF, patients may still struggle to afford to continue to fill and take the medication as prescribed. We found that over one third of patients initiated on sacubitril/valsartan were nonadherent over the next 180 days. The refill patterns suggest that almost half of nonadherent patients discontinued sacubitril/valsartan completely. Whether this occurred because of cost, hemodynamic, renal, or other intolerance would be of interest to investigate in future studies. Our analyses revealed 2 factors that may have contributed. Sacubitril/valsartan was tested in the PARADIGM-HF trial in patients with chronic symptomatic HFrEF who were able to tolerate an ACEi or ARB. 5 However, we found that many patients initiated on sacubitril/valsartan had not filled a prescription for an ACEi/ARB in the 3 months prior. Patients who were not previously on an ACEi or ARB were more likely to be nonadherent/discontinue therapy. In the PARADIGM-HF trial, almost 20% of patients had to discontinue the study during either the enalapril or sacubitril/valsartan run-in phase, primarily because of adverse events or abnormal laboratory values. 5 Our findings suggest that patients who are not taking an ACEi/ARB before starting sacubitril/valsartan may be less likely to tolerate it, leading to discontinuation. It is possible that other patients were prescribed sacubitril/valsartan outside of the recommended route or indication (eg, New York Heart Association functional class I, administered without 36-hour ACEi washout period), and this may have also adversely impacted real-world tolerability. Furthermore, we found that Black patients were more often nonadherent. Although the reasons for nonadherence/ discontinuation are unknown, Blacks may have a strong vasoactive response, possibly because of the prevention of natriuretic peptide breakdown via neprilysin inhibition as they are relatively deficient in natriuretic peptides. 32, 33 Further work is needed to understand tolerability of sacubitril/valsartan in Black individuals. As previously mentioned, enrollment of Black participants in PARADIGM-HF was low (5% of total participants), 5 compared with 17% of those initiating sacubitril/valsartan in our study, underscoring the importance of examination of real-world data such as these to determine effectiveness of new therapies.
Limitations
There are important limitations to acknowledge to aid in interpretation of these findings. First, the data source includes patients enrolled in private and Medicare Advantage health plans with pharmacy benefits, and findings in other populations may differ. Second, we used billing codes to identify patients with HFrEF. Though a billing code for systolic HF has a high positive predictive value and is specific for a reduced EF, it not very sensitive. 10 This could result in an underestimation of the number of patients with HFrEF on an ACEi/ARB. However, many patients may be taking an ACEi/ARB in the presence of a reduced EF, but have no HF symptoms, and would therefore not be eligible to switch to sacubitril/valsartan. As such, the true denominator of patients eligible for sacubitril/valsartan is likely to be smaller than the number of individuals with HFrEF taking an ACEi/ARB in this study.
Conclusions
Despite FDA approval and a strong recommendation for use in the HF guidelines, the adoption of sacubitril/valsartan in clinical practice has been slow. High insurer-paid and patient OOP costs represent an important potential barrier to use and continuation. Additional real-world data are needed to determine the effectiveness and impact on outcomes of sacubitril/valsartan in patients who were not well represented in PARADIGM-HF. Among those who were adherent (proportion of days covered ≥80%) to sacubitril/ valsartan, the proportion that changed dose during the 180 days after initiation by starting dose are shown.
SOURCES OF FUNDING
